Stockscreener 앱 받기
24.28
2.75%
0.65
시간 외 거래:
24.28
전일 마감가:
$23.63
열려 있는:
$23.51
하루 거래량:
479.91K
Relative Volume:
0.65
시가총액:
$1.61B
수익:
-
순이익/손실:
$-137.95M
주가수익비율:
-9.625
EPS:
-2.5226
순현금흐름:
$-107.11M
1주 성능:
-13.47%
1개월 성능:
-13.59%
6개월 성능:
+70.87%
1년 성능:
+112.80%
1일 변동 폭
$23.27
$24.97
1주일 범위
$22.80
$28.40
52주 변동 폭
$10.29
$30.99
Bicara Therapeutics Inc Stock (BCAX) Company Profile
명칭
Bicara Therapeutics Inc
전화
617-468-4219
주소
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Compare BCAX vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
24.28 | 1.63B | 0 | -137.95M | -107.11M | -2.5226 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-25 | 개시 | BofA Securities | Buy |
| 2026-01-29 | 개시 | Citizens JMP | Mkt Perform |
| 2026-01-08 | 개시 | BTIG Research | Buy |
| 2025-12-18 | 개시 | Mizuho | Neutral |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-05-23 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2025-04-17 | 개시 | Wells Fargo | Underweight |
| 2025-02-06 | 개시 | Wedbush | Outperform |
| 2024-12-06 | 개시 | H.C. Wainwright | Buy |
| 2024-11-05 | 개시 | Rodman & Renshaw | Buy |
| 2024-10-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-08 | 개시 | Morgan Stanley | Overweight |
| 2024-10-08 | 개시 | Stifel | Buy |
| 2024-10-08 | 개시 | TD Cowen | Buy |
모두보기
Bicara Therapeutics Inc 주식(BCAX)의 최신 뉴스
Walleye Capital LLC Makes New $10.49 Million Investment in Bicara Therapeutics Inc. $BCAX - marketbeat.com
Bicara Therapeutics (BCAX) awards 285,000 stock options to CFO Jennifer Larson - Stock Titan
Bicara Therapeutics (BCAX) CFO Jennifer Larson submits initial Form 3 - Stock Titan
Bicara Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Bicara shakes up leadership ahead of CEO departure; J&J's John Reed joins Madrigal's board - Endpoints News
Dimensional Fund Advisors LP Increases Stock Position in Bicara Therapeutics Inc. $BCAX - marketbeat.com
Bicara Therapeutics Inc. Common Stock (NASDAQ: BCAX) Stock Price, News & Analysis - kalkine.ca
Analysts Offer Insights on NA Companies: Enhanced Group (ENHA), MNTN, Inc Class A (MNTN) and Bicara Therapeutics Inc. (BCAX) - The Globe and Mail
Leadership Shake-Up And Ficerafusp Alfa Milestone Timeline Might Change The Case For Investing In Bicara Therapeutics (BCAX) - Yahoo Finance
Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results - webull.com
Bicara Therapeutics CEO Claire Mazumdar Executes Stock Option and Sells Shares Under Rule 10b5-1 Plan - Kalkine Media
Bicara Therapeutics CFO Ivan Hyep Executes Sale of 12,500 Shares via 10b5-1 Plan - Kalkine Media
Claire Mazumdar Sells 10,000 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock - marketbeat.com
Bicara Therapeutics (NASDAQ:BCAX) COO Sells $524,625.00 in Stock - marketbeat.com
Ivan Hyep Sells 12,500 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock - marketbeat.com
Bicara Therapeutics Insider Sold Shares Worth $524,533, According to a Recent SEC Filing - marketscreener.com
Bicara Therapeutics Insider Sold Shares Worth $279,750, According to a Recent SEC Filing - marketscreener.com
Bicara Therapeutics (BCAX) CFO exercises options, sells 12,500 shares under 10b5-1 plan - Stock Titan
Bicara Therapeutics (BCAX) CEO exercises 10K options and sells 10K shares under plan - Stock Titan
Bicara Therapeutics (BCAX) President & COO exercises 18,750 options and sells 18,750 shares - Stock Titan
Bicara Therapeutics: My Optimism Is Building Despite Recent Market Headwinds (NASDAQ:BCAX) - Seeking Alpha
BCAX Maintained by Wells Fargo -- Price Target Raised to $23.00 - GuruFocus
Wells Fargo & Company Boosts Bicara Therapeutics (NASDAQ:BCAX) Price Target to $23.00 - marketbeat.com
Bicara Therapeutics (NASDAQ:BCAX) Stock Price Expected to Rise, BTIG Research Analyst Says - MarketBeat
Mizuho raises Bicara Therapeutics stock price target on HNSCC positioning - Investing.com
Mizuho raises Bicara Therapeutics stock price target on HNSCC positioning By Investing.com - Investing.com Nigeria
BCAX SWOT Analysis: Financial Losses Highlighted in 10-Q Filing - GuruFocus
Bicara Therapeutics announces CEO transition, CFO appointment By Investing.com - Investing.com UK
Bicara Therapeutics stock price target raised to $39 by BTIG - Investing.com Australia
Bicara Therapeutics Inc. Stock 12‑Month Price Target Raised to $32.46, Implies 17% Upside - TradingView
Bicara Therapeutics (BCAX) deepens R&D investment while holding $497M in cash - Stock Titan
Bicara Therapeutics Inc. 2026: Revenue ($55.76M), Net income ($55.44M), EPS ($0.82) — 10-Q Summary - TradingView
Bicara Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Morgan Stanley raises Bicara Therapeutics stock price target on cash runway - Investing.com
Bicara Therapeutics' Cancer Study On Track for 2026 Enrollment, Wedbush Says - marketscreener.com
Bicara Therapeutics Inc. Common Stock Q2 2026 Earnings Call Summary - Yahoo Finance
Bicara Q2 2026 slides: leadership shift amid rising spend By Investing.com - Investing.com Canada
Mizuho Securities Adjusts Bicara Therapeutics PT to $20 From $18, Maintains Neutral Rating - marketscreener.com
Bicara Therapeutics (NASDAQ:BCAX) Shares Gap DownHere's Why - marketbeat.com
Transcript : Bicara Therapeutics Inc., Q2 2026 Earnings Call, Aug 11, 2026 - marketscreener.com
Form 8K Bicara Therapeutics Inc For: 11 August By Investing.com - Investing.com Nigeria
Wedbush Adjusts PT on Bicara Therapeutics to $33 From $30, Keeps Outperform Rating - marketscreener.com
Bicara Therapeutics (NASDAQ:BCAX) Posts Earnings Results, Hits Expectations - marketbeat.com
BCAX: Leadership transitions and strong FICERA data drive momentum toward commercialization and growth - TradingView
Bicara Therapeutics Q2 EPS of $(0.82) beats estimates - scanx.trade
Earnings call transcript: Bicara Therapeutics posts Q2 2026 loss as shares fall 16.7% - Investing.com
Bicara Therapeutics stock gains 3% as pivotal trial enrollment advances - Yahoo Finance
Bicara Therapeutics Q2 Earnings Call Highlights - MarketBeat
Bicara Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Bicara Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Bicara Therapeutics Inc (BCAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):